Innovative retatrutide, a twin -action drug targeting both GLP-1 and GIP receptors, is creating considerable interest within the weight loss community. Preliminary clinical trials have demonstrated impressive decreases in body mass and gains in metabolic markers for individuals with excess weight . Scientists believe this unique approach could sig